Mounjaro coupons & savings
tirzepatide · manufacturer programs, telehealth bundles, discount cards
Jump to section
Mounjaro is FDA-approved for type 2 diabetes. Lilly's commercial savings card offers significant cost reduction for insured T2D patients.
Your options
- Manufacturer
Mounjaro Savings Card
as low as $25/monthEligibility: T2D diagnosis + commercial insurance that covers Mounjaro. Not eligible for Medicare, Medicaid, federal programs.
- Discount card
GoodRx coupon
~$995/monthEligibility: No eligibility restrictions.
Important notes
- Mounjaro is for diabetes; weight-loss patients should look at Zepbound (same active ingredient, weight-loss indication).
- Off-label Mounjaro for weight loss is generally not covered by insurance.
Mounjaro and Zepbound are the same drug — the price split is about the label
Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly. The difference is the FDA-approved indication: Mounjaro is approved for type 2 diabetes, Zepbound for chronic weight management (and now obstructive sleep apnea). That labeling split is what determines your cheapest path, because insurers cover the on-label use.
If you have type 2 diabetes, Mounjaro is the version your plan is likely to cover, and coverage is your cheapest route. If your goal is weight loss, Zepbound is the on-label version with weight-loss savings programs (including LillyDirect self-pay vials) — pursuing Mounjaro off-label for weight loss usually means no coverage and a higher bill for the identical molecule.
If you have type 2 diabetes: how to get Mounjaro cheapest
Start with coverage. Commercial plans generally cover Mounjaro for diabetes, and Lilly offers a Mounjaro savings card for commercially insured, covered patients that can substantially cut the copay — subject to the same kind of introductory-then-higher structure and federal-exclusion rules as other manufacturer cards. Medicare and Medicaid patients cannot use the card but usually have diabetes coverage through their plan.
Check your formulary tier and prior-authorization requirement; tirzepatide often needs a PA form your prescriber submits. If coverage is denied, a discount card trims only a little off the high branded list price (around $995 retail) — appeal first if you have the diagnosis.
Off-label for weight loss: the expensive mismatch
Using Mounjaro off-label to lose weight is typically the most expensive way to take tirzepatide: the off-label use is rarely covered, and you cannot access the weight-management savings programs that exist for Zepbound. Since it is literally the same active ingredient, there is no efficacy reason to pay more for the diabetes label.
The cost-smart move for a weight-loss goal is to ask a prescriber about Zepbound, which has both an on-label coverage pathway and the LillyDirect self-pay vial route. Same drug, a savings ecosystem that actually applies to you.
Charity and manufacturer assistance: what is actually open
Status read on each program’s own site on September 16, 2026
3 of the 10 programs below were closed to new applicants on that date, including every charity fund that pays toward a weight-loss GLP-1. We have no relationship with any of them and cannot influence an application. Fund status changes without notice, so confirm on the program’s own page before you count on it.
- Closed
TotalAssist (Patient Advocate Foundation; merged with PAN Foundation)
Obesity fund
The catch: This is the one charity fund built for weight-loss drugs, and it is closed. Its own rules also require health insurance that already covers the expense, so a cash-pay patient would not qualify even when it is open.
- Income limit as stated
- Have an income at or less than 300% of the Federal Poverty Level, adjusted for your regional Cost of Living Index (COLI)
- Insurance requirement
- Have health insurance that covers your qualifying expenses (fund list row: “Health insurance (any)”)
- Award
- $1,000 guaranteed award | $2,000 maximum award
- Phone
- 866-512-3861 (Mon–Fri 8:30am–5:30pm ET)
Status checked: Closed to new applicants when we checked the program's own page on September 16, 2026. Source
- Closed
TotalAssist (Patient Advocate Foundation; merged with PAN Foundation)
Type 2 diabetes (T2DM) fund
The catch: Closed, and it was never open to everyone: this fund requires government-insured coverage, so commercially insured and uninsured patients are ineligible. The companion type 2 diabetes health equity fund is closed as well.
- Income limit as stated
- Have an income at or less than 500% of the Federal Poverty Level, adjusted for your regional Cost of Living Index (COLI)
- Insurance requirement
- Have government-insured coverage that covers your qualifying expenses (fund list row: “Government-insured coverage (Medicare, Medicaid, or TRICARE)”)
- Award
- $1,500 guaranteed award | $2,000 maximum award
- Phone
- 866-512-3861 (Mon–Fri 8:30am–5:30pm ET)
Status checked: Closed to new applicants when we checked the program's own page on September 16, 2026. Source
- Open
TotalAssist (program-level rules)
Program-wide eligibility (nearly 150 funds)
The catch: The program runs, but you can only apply to a fund that is open, and both funds that reach GLP-1s — obesity and type 2 diabetes — were closed on the date checked. A closed fund offers a notification sign-up, not a waitlist queue.
- Income limit as stated
- Have a household income of 500% or less than the Federal Poverty Level (FPL) guidelines, adjusted by the Cost-of-Living Index (COLI) for where the patient lives — with the exception: “Household income of 300% or less than the Federal Poverty Level (only our obesity fund)”
- Insurance requirement
- Have active insurance coverage that includes coverage for pharmaceutical products; the required insurance type varies by fund
- Award
- Varies by fund; grants run on an “individual 12-month rolling grant cycle”
- Phone
- 866-512-3861
Status checked: Open on September 16, 2026. Source
- Closed
HealthWell Foundation
Type 2 Diabetes fund
The catch: HealthWell has no obesity or weight-management fund at all, so a weight-loss prescription has no route here. The type 2 diabetes fund is the only one that reaches a GLP-1, and it is closed: “This fund is temporarily closed to new patients due to lack of sufficient funding.”
- Income limit as stated
- 300–500% of the Federal Poverty Level (fund page); program-wide, “up to 400 or 500 percent of the Federal Poverty Level (somewhat more in cities where the cost of living is higher)”
- Insurance requirement
- “some form of health insurance (private insurance, Medicare, Medicaid, TriCare, etc.) that covers part of the cost of your treatment”; “Drug discount cards do not qualify as insurance.”
- Award
- $1,000 per patient, grant period 12 months
- Phone
- (800) 675-8416 (Mon–Fri 9am–5pm ET)
Status checked: Closed to new applicants when we checked the program's own page on September 16, 2026. Source
- Open
Novo Nordisk Patient Assistance Program (PAP)
Manufacturer patient assistance program (free medicine)
The catch: Ozempic is the only GLP-1 on the product list. Wegovy and Saxenda are not on it, so there is no free-medicine route to a branded obesity GLP-1 from Novo Nordisk. For Ozempic the program takes uninsured patients only, at or below 200% of the federal poverty level.
- Income limit as stated
- Ozempic (uninsured): “Total household income must be at or below 200% of the federal poverty level”; insulins and all other products: “Total household income must be at or below 400% of the federal poverty level”
- Insurance requirement
- Must have Medicare or no insurance; private or commercial insurance makes a patient ineligible. For Ozempic, uninsured patients only — Medicare Part D patients are no longer eligible for Ozempic through PAP.
- Award
- Medicine at no cost; approval lasts 12 months for uninsured patients, through the end of the calendar year for Medicare patients
- Phone
- 1-866-310-7549 (Mon–Fri 8am–8pm ET)
Status checked: Open on September 16, 2026. Source
- Open
Lilly Cares Foundation
Lilly Cares Patient Assistance Program
The catch: The only GLP-1 offered is Trulicity, a type 2 diabetes drug. Zepbound and Mounjaro appear in no medication group and on no Available Medications page, so tirzepatide has no free-medicine route here. Private commercial insurance disqualifies.
- Income limit as stated
- Group 1 Medications (at or below 300% FPL); Group 2 Medications (at or below 400% FPL); Group 3 & Group 4 Medications (at or below 500% FPL) — 2026 FPL guidelines. Household of 1/2/3/4 for Group 1: $47,880 / $64,920 / $81,960 / $99,000.
- Insurance requirement
- For Group 1, 2 and 3 medications, which includes Trulicity: “1) You have no insurance, or 2) you have Medicare Part D (not applicable to infused medications), or 3) you have Medicare Part B but have no supplemental or secondary insurance”
- Award
- Free medication; enrollment generally lasts 12 months or to the end of the enrollment period
- Phone
- 1-800-545-6962
Status checked: Open on September 16, 2026. Source
- Open
Patient Advocate Foundation
Case Management Services & MedCareLine; Financial Aid Funds
The catch: Case management is advocacy, not money: it does not pay for medication. It is worth a call for an insurance denial or appeal. The grant arm is TotalAssist, whose obesity and type 2 diabetes funds are closed.
- Income limit as stated
- No income threshold is published for case management; TotalAssist income limits apply to grants
- Insurance requirement
- No insurance requirement is stated for advocacy; case management is offered to patients “facing a chronic, life-threatening or debilitating diagnosis”
- Award
- Case management carries no grant; TotalAssist grants vary by fund
- Phone
- Case Management (800) 532-5274 (Mon–Fri 8:30am–5pm ET); TotalAssist (866) 512-3861; Financial Aid Funds (855) 824-7941
Status checked: Open on September 16, 2026. Source
- Directory only
NeedyMeds
Information directory and free drug discount card
The catch: NeedyMeds awards no money. It lists other people's programs and issues a discount card — and a discount card is not insurance, which matters because HealthWell states “Drug discount cards do not qualify as insurance.” for its own eligibility.
- Income limit as stated
- None for the discount card: “Can be used by anyone — no financial, age, or residency restrictions”
- Insurance requirement
- None; the card is usable with or without insurance
- Award
- No grant. The card is advertised as “Save up to 80%” on prescriptions.
- Phone
- 800-503-6897 (toll-free helpline)
Status checked: Directory only on September 16, 2026. Source
- Directory only
RxAssist
Directory of patient assistance programs
The catch: A lookup tool, not a funder: no money, no grants, no application, and no patient helpline published on the site. Use it to find manufacturer programs, not to pay for a prescription.
- Income limit as stated
- None — RxAssist awards nothing; income rules belong to the programs it lists
- Insurance requirement
- None stated
- Award
- No award; directory only
- Phone
- No patient helpline published on the site
Status checked: Directory only on September 16, 2026. Source
- Open
AZ&Me Prescription Savings Program (AstraZeneca)
Manufacturer patient assistance program
The catch: No GLP-1 for obesity is offered by this program, and its two diabetes drugs stopped taking new patients: “Effective May 1, 2026, the AZ&Me program will no longer accept new patients for FARXIGA and XIGDUO XR”. Any commercial insurance disqualifies.
- Income limit as stated
- Annual adjusted gross income must be at or below 300% of the Federal Poverty Level (FPL) for Primary and Specialty Medications; 500% of FPL for Rare Disease Medications
- Insurance requirement
- “Not have any commercial (private or employer-sponsored) insurance or government insurance other than Medicare”
- Award
- Medication at no cost, up to a 90-day supply per fill
- Phone
- 1-800-292-6363 (Mon–Fri 9:00am–6:00pm ET)
Status checked: Open on September 16, 2026. Source
Manufacturer copay cards. The Zepbound, Mounjaro, Wegovy and Ozempic savings cards all exclude patients in a government program. The Wegovy terms put it plainly: “Patient is not eligible if he/she is enrolled in any federal or state health care program with prescription drug coverage, such as Medicaid, Medicare, VA, DOD, TRICARE, or any similar federal or state health care program”. If you are on Medicare or Medicaid, the $25 card price is not available to you, whatever the ad says.
Compounded GLP-1s. No program reviewed covers compounded semaglutide or tirzepatide. TotalAssist limits approved medications to products that are “FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines”. Manufacturer programs supply only their own branded products.
Telehealth prescriptions. No program reviewed publishes a telehealth exclusion on its own site. Where a prescription was written is not something these programs ask about in their published rules.
More on Mounjaro
Frequently asked
What's the cheapest way to get Mounjaro?+
Based on the programs currently tracked, the lowest sticker price for Mounjaro is "Mounjaro Savings Card" at as low as $25/month. Eligibility varies by program — check the requirements for each option above before counting on a price.
Does insurance cover Mounjaro?+
Insurance coverage for Mounjaro depends on the plan and indication. Many commercial plans cover tirzepatide for FDA-approved uses with prior authorization; off-label use is rarely covered. Check your formulary or run your plan through our insurance coverage tool.
Are coupons for Mounjaro legitimate?+
Manufacturer programs from Mounjaro's maker and federally registered patient assistance foundations are legitimate. Be cautious with discount cards that promise prices far below retail without verifying the dispensing pharmacy is licensed in your state.
What's the best option for Mounjaro right now?+
Editorial pick: Mounjaro Savings Card at as low as $25/month. T2D diagnosis + commercial insurance that covers Mounjaro. Not eligible for Medicare, Medicaid, federal programs. This is a starting point; your situation may favor a different program based on insurance and clinical eligibility.